Introduction：Basic information about CAS 83712-60-1|Defibrotide sodium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Defibrotide sodium |
|---|
| CAS Number | 83712-60-1 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
Defibrotide sodium BiologicalActivity
| Description | Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. Defibrotide sodium can be used for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) research[1]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/ImmunologyResearch Areas >>Metabolic Disease |
|---|
| In Vitro | Defibrotide sodium’s anti-inflammatory effects occur via agonism at adenosine A1 and A2 receptors, which reduces expression of intracellular adhesion molecule-1 and inhibits release of inflammatory mediators[1]. Defibrotide sodium inhibits platelet aggregation by enhancing production of prostaglandins I2 and E2 and stimulates fibrinolysis via increasing tPA activity and inhibiting plasminogen activator inhibitor type 1 activity[1]. Defibrotide sodium also decreases production of tissue factor and increases production of tissue factor pathway inhibitor, resulting in decreased activation of the extrinsic coagulation cascade and fibrin deposition[1]. Defibrotide sodium protects against endothelial cell damage mediated by tumor necrosis factor α and fludarabine-induced activation and apoptosis[1]. |
|---|
| In Vivo | Intracarotid (i.c.) administration of Defibrotide sodium (64 mg/kg bolus plus 64 mg/kg/h for 1 h) prior to i.c. thrombin (100 μg/kg) significantly reduces the ability of thrombin to induce cranial thromboembolism in rabbits[2]. Intravenous (i.v.) administration of thrombin (20 μg/kg) in rabbits induces a reversible accumulation of radiolabelled platelets into the thoracic circulation which is significantly reduced by i.v. administration of defibrotide (64 mg/kg bolus plus 64 mg/kg/h for 1 h) prior to i.v. thrombin[2]. Intravenous injection of human thrombin (1250 μg/kg) to mice induces death within the majority of animals which is significantly reduced by pretreatment with defibrotide (150-175 mg/kg, i.v.)[2]. |
|---|
| References | [1]. May T Aziz, et al. Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome. Ann Pharmacother. 2018 Feb;52(2):166-174. [2]. W Paul, et al. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. Br J Pharmacol. 1993 Dec;110(4):1565-71. |
|---|
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
